Eden Research has provided a trading update for the 15-month period to March 2026, following a change of year-end from December. The company expects to report revenues of £4.9m (Cav est: £5.0m) and a loss before tax of £2.9m (Cav est: -£2.8m). Adjusted EBITDA loss was greater than our forecast due to a proportion of CAPEX being allocated to administrative expenses. FY26 has seen Eden make significant progress, with notable new approvals for Mevalone and a third temporary approval for Ecovelex. A ....
